Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

M. Scirica, Benjamin; L. Bhatt, Deepak; Braunwald, Eugene; Gabriel Steg, P.; Davidson, Jaime; Hirshberg, Boaz; Ohman, Peter; Frederich, Robert; D. Wiviott, Stephen; B. Hoffman, Elaine; A. Cavender, Matthew; A. Udell, Jacob; R. Desai, Nihar; Mosenzon, Ofri; K. McGuire, Darren; K. Ray, Kausik; A. Leiter, Lawrence; Raz, Itamar

doi:10.1056/nejmoa1307684

Public

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Shared by NobleBlocks on Oct 2, 2013 • 12:00 AM UTC

Authors:

B. Scirica

Deepak L. Bhatt

E. Braunwald

Abstract

BACKGROUND The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular even...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!